Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Skin Neoplasms 2Lymphoma 2Melanoma 1Lymphoma, T-Cell 1Kidney Neoplasms 1

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × zanolimumab × Clear all
NCT00071071 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
25 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00071084 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
22 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡